Prompted by the suggested importance of respiration for the pathophysiology of panic disorder, we studied the influence of serotonin reuptake inhibitors (SRIs) as well as other serotonin-modulating compounds on respiration in freely moving rats. The effect on respiration after acute administration of compounds enhancing synaptic levels of serotonin, that is, the serotonin reuptake inhibitors paroxetine and fluoxetine, the serotonin-releasing agents m-chlorophenylpiperazine and d-fenfluramine, and the selective 5-HT1A antagonist WAY-100635, were investigated. All serotonin-releasing substances decreased respiratory rate in unrestrained, awake animals, suggesting the influence of serotonin on respiratory rate under these conditions to be mainly inhibitory. In line with a previous study, rats administered fluoxetine for 23 days or more, on the other hand, displayed an enhanced respiratory rate. The results reinforce the assumption that the effect of subchronic administration of a serotonin reuptake inhibitor on certain serotonin-regulated parameters may be opposite to that obtained after acute administration. We suggest that our observations may be of relevance for the fact that acute administration of SRIs, d-fenfluramine, or m-chlorophenylpiperazine often is anxiogenic in panic disorder patients, and that weeks of administration of an SRI leads to a very effective prevention of panic.
Abelson JL, Nesse RM, Weg JG, Curtis GC ( 1996) Respiratory psychophysiology and anxiety: cognitive intervention in the doxapram model of panic. Psychosom Med58: 302-313.
2.
Abelson JL, Weg JG, Nesse RM, Curtis GC ( 2001) Persistent respiratory irregularity in patients with panic disorder. Biol Psychiatry49: 588-595.
3.
Aghajanian GK, Graham AW, Sheard MH ( 1970) Serotonin-containing neurons in brain: depression of firing by monoamine oxidase inhibitors. Science169: 1100-1102.
4.
Annerbrink K., Olsson M., Melchior LK, Hedner J., Eriksson E. ( 2003) Serotonin depletion increases respiratory variability in freely moving rats: implications for panic disorder. Int J Neuropsychopharmacol6: 51-56.
5.
Arborelius L., Nomikos GG, Hertel P., et al. (1996) The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with citalopram. Naunyn Schmiedebergs Arch Pharmacol353: 630-640.
6.
Bach KB, Lutcavage ME, Mitchell GS ( 1993) Serotonin is necessary for short-term modulation of the exercise ventilatory response. Respir Physiol91: 57-70.
7.
Battaglia M. ( 2002) Beyond the usual suspects: a cholinergic route for panic attacks. Mol Psychiatry7: 239-246.
8.
Battaglia M., Pesenti-Gritti P., Medland SE, Ogliari A., Tambs K., Spatola CA ( 2009) A genetically informed study of the association between childhood separation anxiety, sensitivity to CO(2), panic disorder, and the effect of childhood parental loss. Arch Gen Psychiatry66: 64-71.
9.
Battaglia M., Pesenti-Gritti P., Spatola CA, Ogliari A., Tambs K. ( 2008) A twin study of the common vulnerability between heightened sensitivity to hypercapnia and panic disorder. Am J Med Genet B Neuropsychiatr Genet147B: 586-593.
10.
Bell C., Forshall S., Adrover M., et al. (2002) Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol16: 5-14.
Blier P., De Montigny C. ( 1985) Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors . Neuroscience16: 949-955.
13.
Blier P., De Montigny C. ( 1990) Electrophysiological investigation of the adaptive response of the 5-HT system to the administration of 5-HT1A receptor agonists. J Cardiovasc Pharmacol15(Suppl 7): S42-48.
14.
Charney DS, Woods SW, Goodman WK, Heninger GR ( 1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl)92: 14-24.
15.
Choi H., Liao WL, Newton KM, et al. (2005) Respiratory abnormalities resulting from midcervical spinal cord injury and their reversal by serotonin 1A agonists in conscious rats. J Neurosci25: 4550-4559.
16.
Den Boer JA, Westenberg HG ( 1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline . Int Clin Psychopharmacol3: 59-74.
17.
Edwards E., Whitaker-Azmitia PM, Harkins K. ( 1990) 5-HT1A and 5-HT1B agonists play a differential role on the respiratory frequency in rats. Neuropsychopharmacology3: 129-136.
18.
Eriksson E., Engberg G., Bing O., Nissbrandt H. ( 1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology20: 287-296.
19.
Feldman JL, Mitchell GS, Nattie EE ( 2003) Breathing: rhythmicity, plasticity, chemosensitivity. Annu Rev Neurosci26: 239-266.
20.
Fornal CA, Metzler CW, Gallegos RA, Veasey SC, Mccreary AC, Jacobs BL ( 1996) WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther278: 752-762.
21.
Forster EA, Cliffe IA, Bill DJ, et al. (1995) A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. Eur J Pharmacol281: 81-88.
22.
Garattini S., Mennini T., Samanin R. ( 1987) From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake. Ann N Y Acad Sci499: 156-166.
23.
Gorman JM, Askanazi J., Liebowitz MR, et al. (1984) Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry141: 857-861.
24.
Gorman JM, Fyer MR, Goetz R., et al. (1988) Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry45: 31-9.
25.
Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM ( 2006) Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry59: 816-820.
26.
Henderson DR, Konkle DM, Mitchell GS ( 1999) Effects of serotonin re-uptake inhibition on ventilatory control in goats. Respir Physiol115: 1-10.
27.
Hjorth S. ( 1993) Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem60: 776-779.
28.
Invernizzi R., Bramante M., Samanin R. ( 1996) Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav54: 143-147.
29.
Johnson PL, Hollis JH, Moratalla R., Lightman SL, Lowry CA ( 2005) Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats. J Psychopharmacol19: 327-341.
30.
Kasamo K., Suzuki T., Tada K., et al. (2001) Endogenous 5-HT tonically inhibits spontaneous firing activity of dorsal hippocampus CA1 pyramidal neurons through stimulation of 5-HT(1A) receptors in quiet awake rats: in vivo electrophysiological evidence . Neuropsychopharmacology24: 141-151.
31.
Kent JM, Papp LA, Martinez JM, et al. (2001) Specificity of panic response to CO(2) inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am J Psychiatry158: 58-67.
32.
Klein DF ( 1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry50: 306-317.
33.
Laferrere B., Wurtman RJ ( 1989) Effect of D-fenfluramine on serotonin release in brains of anaesthetized rats. Brain Res504: 258-263.
34.
Lee YJ, Curtis GC, Weg JG, Abelson JL, Modell JG, Campbell KM ( 1993) Panic attacks induced by doxapram. Biol Psychiatry33: 295-297.
35.
Liebowitz MR, Fyer AJ, Gorman JM, et al. (1984) Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry41: 764-770.
36.
Manzke T., Guenther U., Ponimaskin EG, et al. (2003) 5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science301: 226-229.
37.
Martin-Body RL, Grundy HR ( 1985) Effects of neurotoxin-induced brainstem lesions on the respiratory responses of conscious rats. Clin Exp Pharmacol Physiol12: 427-437.
38.
Martinez JM, Kent JM, Coplan JD, et al. (2001) Respiratory variability in panic disorder . Depress Anxiety14: 232-237.
39.
Mendelson WB, Martin JV, Rapoport DM ( 1990) Effects of buspirone on sleep and respiration. Am Rev Respir Dis141: 1527-1530.
40.
Mitchell GS, Smith CA, Vidruk H., Jameson LC, Dempsey JA ( 1983) Effects of p-chlorophenylalanine on ventilatory control in goats. J Appl Physiol54: 277-283.
41.
Mlinar B., Tatini F., Ballini C., Nencioni S., Della Corte L., Corradetti R. ( 2005) Differential autoinhibition of 5-hydroxytryptamine neurons by 5-hydroxytryptamine in the dorsal raphe nucleus. Neuroreport16: 1351-1355.
42.
Modigh K., Westber P., Eriksson E. ( 1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol12: 251-261.
43.
Mortimore C., Anderson IM ( 2000) d-Fenfluramine in panic disorder: a dual role for 5-hydroxytryptamine . Psychopharmacology (Berl)149: 251-258.
44.
Mulkey DK, Stornetta RL, Weston MC, et al. (2004) Respiratory control by ventral surface chemoreceptor neurons in rats. Nat Neurosci7: 1360-1369.
45.
Nardi AE, Freire RC, Zin WA ( 2008a) Panic disorder and control of breathing. Respir Physiol Neurobiol.
46.
Nardi AE, Freire RC, Zin WA (2009) Panic disorder and control of breathing. Respir Physiol Neurobiol167(1): 133-143.
47.
Nardi AE, Valenca AM, Nascimento I., et al. (2008b) A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls. Depress Anxiety25: 847-853.
48.
Nutt DJ, Glue P. ( 1989) Clinical pharmacology of anxiolytics and antidepressants: a psychopharmacological perspective. Pharmacol Ther44: 309-334.
49.
Olson EB, Jr ( 1987) Ventilatory adaptation to hypoxia occurs in serotonin-depleted rats. Respir Physiol69: 227-235.
50.
Olsson M., Annerbrink K., Bengtsson F., Hedner J., Eriksson E. ( 2004) Paroxetine influences respiration in rats: implications for the treatment of panic disorder. Eur Neuropsychopharmacol14: 29-37.
51.
Papp LA, Klein DF, Gorman JM ( 1993) Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry150: 1149-1157.
52.
Papp LA, Martinez JM, Klein DF, et al. (1997) Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry154: 1557-1565.
53.
Perna G., Battaglia M., Garberi A., Arancio C., Bertani A., Bellodi L. ( 1994) Carbon dioxide/oxygen challenge test in panic disorder . Psychiatry Res52: 159-171.
54.
Pitts FN, Jr, McClure JN, Jr ( 1967) Lactate metabolism in anxiety neurosis. N Engl J Med277: 1329-1336.
55.
Pohl R., Yeragani VK, Balon R., Lycaki H. ( 1988) The jitteriness syndrome in panic disorder patients treated with antidepressants. J Clin Psychiatry49: 100-104.
56.
Preter M., Klein DF ( 2008) Panic, suffocation false alarms, separation anxiety and endogenous opioids. Prog Neuropsychopharmacol Biol Psychiatry32: 603-612.
57.
Richerson GB ( 2004) Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat Rev Neurosci5: 449-461.
58.
Richerson GB, Wang W., Hodges MR, Dohle CI, Diez-Sampedro A. ( 2005) Homing in on the specific phenotype(s) of central respiratory chemoreceptors. Exp Physiol90: 259-266; discussion 266-269.
59.
Richter DW, Manzke T., Wilken B., Ponimaskin E. ( 2003) Serotonin receptors: guardians of stable breathing. Trends Mol Med9: 542-548.
60.
Severson CA, Wang W., Pieribone VA, Dohle CI, Richerson GB ( 2003) Midbrain serotonergic neurons are central pH chemoreceptors . Nat Neurosci6: 1139-1140.
61.
Sharp T., Bramwell SR, Grahame-Smith DG ( 1989) 5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol96: 283-290.
62.
Sheehan DV, Raj AB, Harnett-Sheehan K., Soto S., Knapp E. ( 1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study . Acta Psychiatr Scand88: 1-11.
63.
Sinha S., Papp LA, Gorman JM ( 2000) How study of respiratory physiology aided our understanding of abnormal brain function in panic disorder. J Affect Disord61: 191-200.
64.
Stahl SM ( 1998) Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects . J Affect Disord51: 215-235.
65.
Stein MB, Millar TW, Larsen DK, Kryger H. ( 1995) Irregular breathing during sleep in patients with panic disorder. Am J Psychiatry152: 1168-1173.
66.
Stone RA, Worsdell YM, Fuller RW, Barnes PJ ( 1993) Effects of 5-hydroxytryptamine and 5-hydroxytryptophan infusion on the human cough reflex. J Appl Physiol74: 396-401.
67.
Struzik L., Duffin J., Vermani M., Hegadoren K., Katzman MA ( 2002) Effects of tryptophan depletion on central and peripheral chemoreflexes in man. Respir Physiol Neurobiol133: 183-195.
68.
Taylor NC, Li A., Green A., Kinney HC, Nattie EE ( 2004) Chronic fluoxetine microdialysis into the medullary raphe nuclei of the rat, but not systemic administration, increases the ventilatory response to CO2. J Appl Physiol97: 1763-1773.
69.
Toru I., Shlik J., Maron E., Vasar V., Nutt DJ ( 2006) Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram . Psychopharmacology (Berl)186: 107-112.
70.
Valic M., Pecotic R., Dogas Z. ( 2008) Phrenic nerve activity is enhanced by 5-HT1A receptor agonist 8-OH-DPAT in spontaneously breathing anesthetized rats. J Physiol Pharmacol59: 17-25.
71.
Van Vliet IM, Westenberg HG, Den Boer JA ( 1996) Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology (Berl)127: 174-180.
72.
Wang X., Dergacheva O., Kamendi H., Gorini C., Mendelowitz D. ( 2007) 5-Hydroxytryptamine 1A/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function . Hypertension50: 368-376.
73.
Wilhelm FH, Trabert W., Roth WT ( 2001) Physiologic instability in panic disorder and generalized anxiety disorder. Biol Psychiatry49: 596-605.
